To study the effects of targeting mETC complexes in liver cancer, SNU-449, PLC/PRF/5 and HepG2 liver cancer cell lines were challenged with six pharmacological inhibitors targeting the four mETC complexes (I, II, III, and IV). The gene discussed is HSPG2; the disease is liver cancer.